Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-HIV Agents | 14 | 2024 | 1275 | 1.170 |
Why?
|
| HIV Infections | 21 | 2024 | 4946 | 1.010 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 9 | 2024 | 76 | 0.860 |
Why?
|
| HIV-1 | 10 | 2024 | 1239 | 0.740 |
Why?
|
| Oxazines | 9 | 2024 | 71 | 0.740 |
Why?
|
| Pyridones | 9 | 2024 | 87 | 0.730 |
Why?
|
| Piperazines | 8 | 2024 | 73 | 0.690 |
Why?
|
| Tenofovir | 6 | 2024 | 158 | 0.550 |
Why?
|
| Weight Gain | 3 | 2024 | 73 | 0.460 |
Why?
|
| Humans | 23 | 2024 | 14077 | 0.310 |
Why?
|
| Female | 18 | 2024 | 8751 | 0.290 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2020 | 468 | 0.290 |
Why?
|
| HIV Integrase Inhibitors | 3 | 2024 | 29 | 0.280 |
Why?
|
| Adult | 15 | 2024 | 5664 | 0.280 |
Why?
|
| Creatinine | 2 | 2024 | 51 | 0.270 |
Why?
|
| Adenine | 3 | 2023 | 88 | 0.260 |
Why?
|
| Emtricitabine | 5 | 2024 | 74 | 0.250 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2019 | 654 | 0.250 |
Why?
|
| Male | 11 | 2024 | 6489 | 0.230 |
Why?
|
| Viral Load | 4 | 2020 | 808 | 0.230 |
Why?
|
| Antiviral Agents | 3 | 2022 | 107 | 0.220 |
Why?
|
| Chronic Pain | 1 | 2022 | 3 | 0.210 |
Why?
|
| Pharmacogenetics | 1 | 2022 | 27 | 0.210 |
Why?
|
| Blood Pressure | 1 | 2024 | 312 | 0.200 |
Why?
|
| Herpesvirus 2, Human | 3 | 2012 | 42 | 0.200 |
Why?
|
| Middle Aged | 8 | 2024 | 3425 | 0.200 |
Why?
|
| Herpes Genitalis | 3 | 2012 | 42 | 0.200 |
Why?
|
| Benzoxazines | 4 | 2023 | 119 | 0.190 |
Why?
|
| Folic Acid | 1 | 2021 | 12 | 0.190 |
Why?
|
| Drug Interactions | 1 | 2021 | 30 | 0.190 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2020 | 38 | 0.180 |
Why?
|
| Acyclovir | 2 | 2012 | 11 | 0.180 |
Why?
|
| Pain | 1 | 2020 | 40 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 186 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 2 | 2021 | 235 | 0.180 |
Why?
|
| Hypertension | 1 | 2024 | 397 | 0.170 |
Why?
|
| South Africa | 9 | 2024 | 7312 | 0.170 |
Why?
|
| Phosphorous Acids | 1 | 2019 | 14 | 0.170 |
Why?
|
| Bone and Bones | 1 | 2019 | 38 | 0.160 |
Why?
|
| Kidney | 1 | 2019 | 46 | 0.160 |
Why?
|
| Stavudine | 1 | 2019 | 78 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 145 | 0.140 |
Why?
|
| Alkynes | 3 | 2022 | 113 | 0.140 |
Why?
|
| Cyclopropanes | 3 | 2022 | 119 | 0.140 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2017 | 56 | 0.140 |
Why?
|
| Treatment Outcome | 4 | 2022 | 867 | 0.130 |
Why?
|
| Hepatitis B | 1 | 2017 | 123 | 0.130 |
Why?
|
| RNA, Viral | 3 | 2019 | 303 | 0.130 |
Why?
|
| Mass Screening | 1 | 2017 | 242 | 0.130 |
Why?
|
| Coinfection | 1 | 2017 | 268 | 0.120 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 542 | 0.120 |
Why?
|
| Young Adult | 6 | 2020 | 2357 | 0.120 |
Why?
|
| DNA, Viral | 3 | 2012 | 165 | 0.120 |
Why?
|
| Alanine | 2 | 2024 | 29 | 0.110 |
Why?
|
| Ulcer | 1 | 2012 | 7 | 0.100 |
Why?
|
| Darunavir | 2 | 2022 | 12 | 0.090 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2019 | 507 | 0.090 |
Why?
|
| Lopinavir | 2 | 2022 | 137 | 0.090 |
Why?
|
| Ritonavir | 2 | 2022 | 137 | 0.090 |
Why?
|
| Contraception | 1 | 2010 | 90 | 0.080 |
Why?
|
| Double-Blind Method | 3 | 2019 | 263 | 0.080 |
Why?
|
| Genitalia, Female | 1 | 2008 | 17 | 0.080 |
Why?
|
| Drug Resistance, Viral | 2 | 2020 | 268 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2020 | 939 | 0.070 |
Why?
|
| Pregnancy | 3 | 2021 | 1815 | 0.070 |
Why?
|
| HIV | 1 | 2010 | 380 | 0.070 |
Why?
|
| Adolescent | 3 | 2020 | 2858 | 0.070 |
Why?
|
| Africa South of the Sahara | 2 | 2020 | 328 | 0.060 |
Why?
|
| Glucuronosyltransferase | 1 | 2024 | 6 | 0.060 |
Why?
|
| Glomerular Filtration Rate | 1 | 2024 | 61 | 0.060 |
Why?
|
| Nitro Compounds | 1 | 2022 | 2 | 0.050 |
Why?
|
| Pyrrolidines | 1 | 2022 | 4 | 0.050 |
Why?
|
| Imidazoles | 1 | 2022 | 9 | 0.050 |
Why?
|
| Thiazoles | 1 | 2022 | 6 | 0.050 |
Why?
|
| Sofosbuvir | 1 | 2022 | 8 | 0.050 |
Why?
|
| Valine | 1 | 2022 | 6 | 0.050 |
Why?
|
| Lamivudine | 1 | 2023 | 86 | 0.050 |
Why?
|
| Carbamates | 1 | 2022 | 12 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 190 | 0.050 |
Why?
|
| Social Stigma | 1 | 2022 | 76 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2021 | 16 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 112 | 0.050 |
Why?
|
| HIV Integrase | 1 | 2020 | 5 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 237 | 0.050 |
Why?
|
| Virus Shedding | 2 | 2012 | 24 | 0.050 |
Why?
|
| Quality of Life | 1 | 2022 | 170 | 0.050 |
Why?
|
| Genotype | 1 | 2021 | 430 | 0.040 |
Why?
|
| Exercise | 1 | 2022 | 203 | 0.040 |
Why?
|
| Body Weight | 1 | 2020 | 110 | 0.040 |
Why?
|
| Uracil | 1 | 2019 | 7 | 0.040 |
Why?
|
| Prodrugs | 1 | 2019 | 10 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 21 | 0.040 |
Why?
|
| Mutation | 1 | 2020 | 299 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 409 | 0.040 |
Why?
|
| Body Composition | 1 | 2020 | 150 | 0.040 |
Why?
|
| Equivalence Trials as Topic | 1 | 2019 | 7 | 0.040 |
Why?
|
| Cervix Uteri | 2 | 2009 | 21 | 0.040 |
Why?
|
| Bone Density | 1 | 2019 | 103 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 271 | 0.040 |
Why?
|
| Uganda | 1 | 2019 | 194 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2018 | 16 | 0.040 |
Why?
|
| Vagina | 2 | 2009 | 91 | 0.040 |
Why?
|
| Specimen Handling | 2 | 2009 | 103 | 0.040 |
Why?
|
| Transaminases | 1 | 2017 | 5 | 0.040 |
Why?
|
| Antigens | 1 | 2017 | 11 | 0.040 |
Why?
|
| Neutropenia | 1 | 2017 | 9 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 210 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 88 | 0.040 |
Why?
|
| Albuminuria | 1 | 2017 | 20 | 0.040 |
Why?
|
| Cities | 1 | 2017 | 37 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2017 | 40 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2017 | 38 | 0.040 |
Why?
|
| Anemia | 1 | 2017 | 41 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 1149 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2017 | 107 | 0.030 |
Why?
|
| Aged | 1 | 2019 | 1650 | 0.030 |
Why?
|
| Recurrence | 1 | 2012 | 27 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 103 | 0.020 |
Why?
|
| HIV Seronegativity | 1 | 2012 | 52 | 0.020 |
Why?
|
| Zambia | 1 | 2012 | 112 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2012 | 104 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 163 | 0.020 |
Why?
|
| Therapeutic Irrigation | 1 | 2008 | 4 | 0.020 |
Why?
|
| Menstrual Hygiene Products | 1 | 2008 | 8 | 0.020 |
Why?
|
| Incidence | 1 | 2010 | 655 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2009 | 367 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2009 | 313 | 0.020 |
Why?
|
| Risk Factors | 1 | 2010 | 1431 | 0.020 |
Why?
|